INR 1179.0
(-0.08%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.96 Billion INR | 13.57% |
2022 | 1.73 Billion INR | -9.62% |
2021 | 1.91 Billion INR | 10.83% |
2020 | 1.73 Billion INR | 26.25% |
2019 | 1.37 Billion INR | -16.21% |
2018 | 1.63 Billion INR | 85.41% |
2017 | 882.46 Million INR | -8.06% |
2016 | 959.82 Million INR | -7.01% |
2015 | 1.03 Billion INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -1.93 Billion INR | -198.35% |
2023 FY | 1.96 Billion INR | 13.57% |
2023 Q4 | 1.96 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 Q2 | 1.66 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2022 Q2 | 1.92 Billion INR | 0.0% |
2022 FY | 1.73 Billion INR | -9.62% |
2022 Q4 | 1.73 Billion INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2022 Q1 | - INR | -100.0% |
2021 Q2 | 2 Billion INR | 0.0% |
2021 Q4 | 1.91 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 Q3 | - INR | -100.0% |
2021 FY | 1.91 Billion INR | 10.83% |
2020 Q2 | 1.48 Billion INR | 0.0% |
2020 FY | 1.73 Billion INR | 26.25% |
2020 Q4 | 1.73 Billion INR | 0.0% |
2020 Q3 | - INR | -100.0% |
2020 Q1 | - INR | -100.0% |
2019 Q3 | - INR | -100.0% |
2019 Q2 | 1.41 Billion INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 FY | 1.37 Billion INR | -16.21% |
2019 Q4 | 1.37 Billion INR | 0.0% |
2018 FY | 1.63 Billion INR | 85.41% |
2018 Q3 | - INR | -100.0% |
2018 Q4 | 1.63 Billion INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2018 Q2 | 1.37 Billion INR | 0.0% |
2017 FY | 882.46 Million INR | -8.06% |
2017 Q2 | 985.03 Million INR | 0.0% |
2017 Q4 | 882.46 Million INR | 0.0% |
2017 Q1 | - INR | -100.0% |
2016 FY | 959.82 Million INR | -7.01% |
2016 Q4 | 959.82 Million INR | 0.0% |
2016 Q1 | - INR | 0.0% |
2015 FY | 1.03 Billion INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Biocon Limited | 307.95 Billion INR | 99.361% |
Blue Jet Healthcare Limited | 2.13 Billion INR | 7.836% |
Concord Biotech Limited | 1.74 Billion INR | -13.11% |
Dishman Carbogen Amcis Limited | 39.53 Billion INR | 95.02% |
Jubilant Ingrevia Limited | 19.94 Billion INR | 90.128% |
Lyka Labs Limited | 884.58 Million INR | -122.57% |
Panacea Biotec Limited | 4.02 Billion INR | 51.027% |
Piramal Pharma Limited | 74 Billion INR | 97.34% |
Supriya Lifescience Limited | 1.05 Billion INR | -85.966% |
Syngene International Limited | 18.93 Billion INR | 89.604% |
TAKE Solutions Limited | 969.78 Million INR | -103.018% |
Zota Health Care Limited | 1.38 Billion INR | -42.306% |